Connecting Capital with Opportunities:


# HKEX as a Trusted Global Capital Raising Centre of Choice

**Bonnie Y Chan** Head of Listing





# **Hong Kong Listing | A Unique Value Proposition**



Global leader in IPOs and IPO funds raised: Ranked No. 1 for seven times since 2009



#### **Today | The New Economy Success**

#### Where we are today


Introduced **WVR**, Secondary Listing and Biotech Listing Reform in 2018

Close to 20 US-listed issuers have sought their "home-coming" listing in Hong Kong, with an emerging trend favoring dual-primary listing over secondary listing, e.g. XPeng

New economy has become the fastestgrowing sector in Hong Kong – since 2018 Listing Reforms, IPOs of new economy companies accounted for 65% of total IPO fundraising

**New Economy stocks** and related structured products account for an increasing portion of ADT







## **Today | The Biotech Story**


Achievements Achievements						
Listing Overview (since new listing regime)		88 Healthcare Issuers Listed	HK\$1,487bn Market Cap		HK\$255bn Fund Raised	
Follow-on Fundraising since April 2018		50 Healthcare Issuers with Equity Follow-on <sup>1</sup>	HK\$200bn Fund Raised			
Policy Enhancements		Guidance Letter on Disclosure for 18A Issuers	18A Issuers i HSCI	inclusion in	Stock Connect inclusion for 18A Issuers	

#### **Competitive Landscape**

in the world in terms of Healthcare IPO
Funds raised since New Listing Regime<sup>2</sup>

		Ecosystem		
	Intermediaries	Hoolthoom and Distant Journe	Research Coverage	
Q <sub>A</sub>		Healthcare and Biotech Issuers		<i></i> /
	<b>Investor Base</b>		Structured Products	

<sup>1.</sup> Include placing, right issue and consideration issue. Does not include new shares issued for the ESOP purpose.





### Opportunities | Continuous Enhancement of our Listing Regime

#### **IFC Competitiveness**



- Constant review to stay "Fit for Purpose" - study underway to create bespoke chapter for large-scale advanced technology companies
- New frameworks to cater for issuer and investor demands e.g. SPACs
- Streamlined process for listing of overseas companies

#### **Market Quality**



- Vigorous eligibility and compliance requirements
- Robust corporate governance and ESG standards

#### **Regulatory Efficiency**



- Active dialogue with stakeholders to identify areas for further enhancement e.g. Project FINI
- New technology to facilitate regulation



### **Enablers | Policy Agenda for 2022**

**1H** 2H **ESG Review (ISSB Climate** IPO Eligibility / WVR IPO Eligibility / **ESG Review (ISSB Climate** Disclosure) - Sub-Suitability - Consultation Disclosure) - Consultation **WVR Suitability Review IFC** committee Competitiveness **Optimisation of IPO Price** Structured Products Rules -Discovery Consultation **Issuers' Annual Reports Updated Guidance on Shell ESG Practice Analysis Listing Newsletter/** Review Companies LIR Newsletter/ Market **Enforcement Bulletin** Listing Committee Report • E-Learning - Trading Quality 2021 **Arrangements ESG Academy Webinar** Listing Newsletter and - Climate **Enforcement Bulletin** Consequential Rule **XBRL for Hong Kong – Joint Further Paperless** FINI - Listing Rules Changes relating to the **Working Group Discussions** Listing Reform -Consultation Regulatory SFC's Code of Conduct Consultation **Efficiency Diversity Repository** 



## Summary | Attractive, Competitive and Trusted Framework for Capital Raising

Leverage our New Economy success to continue building the IPO pipeline welcoming issuers from diverse sectors and geograph

